-
Novel inhibitor insights offer pathway to preventing PXR-associated drug resistance
05/14/2024
See how novel pregnane X receptor inhibitors offer structural understanding behind activator and repressor activity, guiding future drug design research to combat drug resistance
-
Pan-cancer analysis uncovers a new class of promising CAR T–cell immunotherapy targets
05/03/2024
St. Jude found 156 potential targets for chimeric antigen receptor (CAR) T–cell immunotherapy. Explore the discovery’s promise to improve cancer therapies.
-
Unraveling the roles of non-coding DNA explains childhood cancer’s resistance to chemotherapy
05/01/2024
Non-coding DNA variants contribute to acute lymphoblastic leukemia (ALL) chemotherapy resistance. Explore new technology used in the St. Jude-led discovery.
-
Hongbo Chi, PhD named 2023 AAAS Fellow
04/29/2024
The St. Jude immunologist has made valuable contributions to immunometabolism. AAAS is the world’s largest general scientific society.
-
Targeting specific protein regions offers a new treatment approach in medulloblastoma
04/25/2024
Explore how research targeting EP300/CBP protein in Group 3 medulloblastoma may advance targeted pediatric brain tumor treatments by inhibiting bromodomains.
-
Genetics predict type 2 diabetes risk and disparities in childhood cancer survivors
04/23/2024
Learn how ancestry changes genetic risk variants’ impact on type 2 diabetes in childhood cancer survivors & alkylating agent exposure magnifies diabetes risk.
-
Metabolic health before vaccination determines effectiveness of anti-flu response
04/18/2024
Poor metabolic health or dysfunction, not obesity, leads to poor anti-influenza immune responses. Learn about the new St. Jude influenza vaccination research.
-
Andrew Smith, MD, PhD, named chair of Diagnostic Imaging at St. Jude Children’s Research Hospital
04/15/2024
Andrew Smith, MD, PhD, named chair of Diagnostic Imaging at St. Jude Children's Research Hospital. Smith is an expert in the use of artificial intelligence in imaging and medicine.
-
New drug prevents flu-related inflammation and lung damage
04/10/2024
New RIPK3 inhibitor UH15-38 protected models against influenza-induced inflammation and lung injury. Learn how it selectively blocks pathogenic necroptosis.
-
St. Jude survivorship portal brings researchers ‘one-click’ away from discovery
04/09/2024
Learn about the survivorship portal, a part of the St. Jude Cloud ecosystem, and find out how researchers can use the portal to make new discoveries.
-
Targeting vulnerability in B-cell development leads to novel drug combination for leukemia
04/08/2024
Discover how a vulnerability in treatment resistant B-cell acute lymphoblastic leukemia (B-ALL) was uncovered by single-cell analysis of developmental stage.
-
Renowned St. Jude clinician and researcher to receive coveted award at AACR annual meeting
04/04/2024
St. Jude researchers to present their science at AACR annual meeting.
-
Study flips treatment paradigm in bilateral Wilms tumor, shows resistance to chemotherapy may point toward favorable outcomes
03/28/2024
See how chemotherapy resistance in bilateral Wilms tumor implies stromal predominant with favorable outcomes if surgery follows rather than further chemo or biopsy
-
Researchers turn back the clock on cancer cells to offer new treatment paradigm
03/27/2024
Rhabdoid tumor cells were reverted from a cancerous state to normal. Discover how deletion of quality control protein DCAF5 may treat an undruggable cancer.
-
Immunotherapy targeting cancer fusion protein may hold key to treating rare liver cancer
03/19/2024
Explore how a T-cell receptor targeting an oncogenic fusion holds treatment promise in fibrolamellar carcinoma (FLC), a rare liver cancer with poor prognosis.
-
Scientists find core regulatory circuit controlling identity of aggressive leukemia
03/19/2024
Anaplastic large cell lymphoma is an aggressive form of cancer. Learn how a core regulatory circuit & STAT3 in ALCL may lead to new therapeutic opportunities.
-
Change in MYCN-driven cell state opens therapeutic window in high-risk neuroblastoma
03/19/2024
See how mesenchymal to adrenergic cell change mechanism in MYCN-linked neuroblastoma linked to high MYCN levels, driven by KDM4 induction.
-
Role in mitochondrial metabolism paints more complete picture of MCL-1 function
03/18/2024
See how anti-apoptosis oncoprotein MCL-1 also functions in fatty acid metabolism by binding ACSL1 explaining cardiac toxicity in clinical trials
-
Rare inflammatory disease responds best to double inhibition
03/06/2024
Ruxolitinib treats hemophagocytic lymphohistiocytosis (HLH) models better than JAK1 or 2 single inhibitors. Discover its promise in an ongoing clinical trial.
-
St. Jude taps health care start-up veteran as first Senior Vice President of Tech Commercialization
02/20/2024
New VP will work with St. Jude researchers to commercialize discoveries made at St. Jude to benefit more patients.
-
Novel bispecific design improves CAR T–cell immunotherapy for childhood leukemia
02/12/2024
Learn why bispecific chimeric antigen receptor (CAR) T-cell therapy for acute myeloid leukemia (AML) improved treatment, confirmed by artificial intelligence.
-
Sara Federico, MD, named director of the Solid Tumor Division at St. Jude Children’s Research Hospital
02/07/2024
Established clinician researcher will focus on novel treatments and clinical trials for difficult-to-treat childhood cancers.
-
Inaugural class of Damon Runyon– St. Jude Pediatric Cancer Research Fellows announced
02/01/2024
This initiative supports early-career scientists studying pediatric cancer, addressing a funding gap between pediatric and adult cancer research.
-
St. Jude Children’s Research Hospital adds $13 million project to Research Collaboratives Program
01/18/2024
Created as part of the 2022-2027 Strategic Plan, the St. Jude Research Collaboratives program is part of an overall effort by the institution to fund collaborative research addressing complex scientific problems with transformative potential for the diseases treated at St. Jude.
-
Molecular ‘super-glue’ shows promise of cancer drug discovery platform
01/16/2024
Learn how St. Jude created a molecular super-glue to target cancer-related protein casein kinase 1 alpha (CK1α) & how the platform may lead to new treatments.
-
St. Jude Home Care, LLC is first U.S. pediatric home health agency to earn new category of industry certification
01/16/2024
The mobile service was certified by CHAP in pediatrics and home health.
-
HOXA9 tracking reveals RBM5 dual function and therapeutic potential for acute myeloid leukemia
01/12/2024
See how St. Jude researchers use CRISPR-Cas9 to identify RBM5 as a key play in HOXA9-associated leukemia and how RBM5 was shown to have a duel function as splicing factor and transcription factor.
-
Two common biomarkers predict heart risk in asymptomatic childhood cancer survivors
01/11/2024
Find how global longitudinal strain (GLS) & N-terminal-pro-B-type natriuretic peptide (NT-proBNP) improved heart risk predictions in pediatric cancer survivors.
-
Updated genomic landscape for pediatric acute myeloid leukemia enables new treatment possibilities
01/11/2024
Scientists at St. Jude Children’s Research Hospital refined and enhanced the classification system for a type of pediatric leukemia using genomic and transcriptomic analysis.
-
Acute pediatric critical illness definition enables global research
01/08/2024
Find how a new more inclusive consensus definition of acute pediatric critical illness will fuel research across the globe due to St. Jude-led collaboration.
-
A new approach can address antibiotic resistance to Mycobacterium abscessus
01/05/2024
Learn how St. Jude scientists developed a new form of spectinomycin, which overcomes efflux and thus antibiotic resistance in Mycobacterium abscessus.
-
Elusive cytonemes guide neural development, provide signaling ‘express route’
01/02/2024
Discover the first images of cytonemes during mammalian neural development, serving as express routes to establish morphogen gradients and tissue patterning.
